(Q37964271)

26 August 2017

mTOR inhibitor-associated proteinuria in kidney transplant recipients (English)

1 reference

26 August 2017

Fritz Diekmann

1

1 reference

PubMed ID

22137729

26 August 2017

Amado Andrés

series ordinal

2

1 reference

PubMed ID

22137729

26 August 2017

Federico Oppenheimer

series ordinal

3

1 reference

26 August 2017

1 January 2012

1 reference

26 August 2017

Transplantation Reviews

1 reference

26 August 2017

26

1 reference

26 August 2017

1

1 reference

26 August 2017

27-29

1 reference

Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Proteinuria in transplant patients associated with sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Post-rapamycin proteinuria: incidence, evolution, and therapeutic handling at a single center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Proteinuria after renal transplantation affects not only graft survival but also patient survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Early low-grade proteinuria: causes, short-term evolution and long-term consequences in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to Cyclosporine-based immunosuppressive regimens in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Sirolimus interacts with pathways essential for podocyte integrity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2011.10.003

10.1016/J.TRRE.2011.10.003

7 January 2021

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22137729